Related Experiment Video
Updated: May 15, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Self-assembled PROTACs enable glycoproteins degradation in the living cells
Haoyu Chen1, Liu Zang1, Pavel Kielkowski1
1Department of Chemistry, LMU Munich Würmtalstr. 201 81375 Munich Germany pavel.kielkowski@cup.lmu.de.
Abstract:
We report here a two-component proteolysis targeting chimeras (PROTACs) strategy selectively targeting O-GalNAcylated and O-GlcNAcylated proteins for proteasomal degradation, which leads to severe toxicity in human cancer cell lines through perturbation of critical metabolic and signaling pathways governed by glycoproteins. Our approach termed as GlyTAC leverages from metabolic incorporation of easily accessible and cell-permeable peracetylated N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) analogues bearing an azido group into glycoproteins. In the living cells, the azido-modified glycoproteins serve as covalent anchors for the introduction of thalidomide moiety by strain-promoted azide-alkyne cycloaddition (SPAAC) to recruit E3 ligase cereblon (CRBN), resulting in stepwise ubiquitination of 'sensitized' proteins and their degradation by proteasome. We show the efficiency of the system in a series of human cancer cell lines and verify the mechanistic pathway by performing control experiments at each stage of the process. Given the characteristic features of cancer cells including fast nutrient turnover, and overall increase of protein glycosylation, as well as the low cytotoxicity of the individual components, our approach may open a feasible strategy in cancer therapy.
Insights
This study introduces GlyTAC, a novel proteolysis targeting chimera (PROTAC) strategy that degrades cancer cell glycoproteins. GlyTAC utilizes modified sugars to selectively eliminate target proteins, offering a potential new cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Aberrant protein glycosylation is a hallmark of cancer.
- Targeting glycoproteins is a promising strategy for cancer therapy.
- Proteolysis targeting chimeras (PROTACs) offer a method for targeted protein degradation.
Purpose of the Study:
- To develop a novel PROTAC strategy targeting O-GalNAcylated and O-GlcNAcylated proteins.
- To investigate the potential of this strategy for cancer therapy.
- To leverage metabolic incorporation of modified sugars for targeted protein degradation.
Main Methods:
- Metabolic incorporation of azido-modified N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) analogues into glycoproteins.
- Strain-promoted azide-alkyne cycloaddition (SPAAC) to attach a thalidomide moiety, recruiting E3 ligase cereblon (CRBN).
- Induction of ubiquitination and proteasomal degradation of targeted glycoproteins in human cancer cell lines.
Main Results:
- Demonstrated selective degradation of O-GalNAcylated and O-GlcNAcylated proteins in cancer cells.
- Observed significant toxicity in human cancer cell lines due to pathway perturbation.
- Verified the mechanistic pathway through control experiments at each stage.
Conclusions:
- GlyTAC is an efficient two-component PROTAC system for targeted glycoprotein degradation.
- The strategy shows potential for cancer therapy due to cancer-specific glycosylation patterns.
- Further investigation may lead to novel therapeutic approaches for cancer treatment.
More Related Videos
07:22Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
10:30Delivery of Proteins, Peptides or Cell-impermeable Small Molecules into Live Cells by Incubation with the Endosomolytic Reagent dfTAT
Published on: September 2, 2015
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Tagging and Fusion Proteins
The Proteasome Structure
The proteasome is an...
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...